India limits drug trials per investigator but finite expert pool a concern
This article was originally published in SRA
India's Central Drugs Standard Control Organization has issued a new order that restricts the number of clinical trials that an investigator can be involved in to no more than three trials at a time1. The order, issued this month, has come under fire from the Indian Society for Clinical Research, which warns it will be "detrimental" to the progress of quality clinical research in the country.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.